THERAPY DOSSIER · th-5f0efdfaf3cc

Levodopa (L-DOPA)

Drug · AGONIST at the dopamine D3 receptor (direct interaction, disease efficacy); levodopa is a prodrug of dopamine.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: AGONIST at the dopamine D3 receptor (direct interaction, disease efficacy); levodopa is a prodrug of dopamine.
Target: CHEMBL234 (dopamine D3 receptor)
Injury models: TBI
Reported indication: Parkinson's disease (dopamine precursor; approved 1970)
First approval: 1970
Development stage: Approved for Parkinson's; NAION/optic-injury use investigational
ChEMBL record: CHEMBL1009 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: L-DOPA; Larodopa; Dopar; Inbrija; Sinemet component; Rytary component; Duopa component
Note: Not recorded

Clinical trials 7

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00432393 ↗PHASE4completed

Effect of Levodopa-Carbidopa on Visual Function in Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy

Nonarteritic Anterior Ischemic Optic Neuropathy

Enrolment not recorded · Results not recorded

NCT00144209 ↗PHASE3completed

Swiss Restless Legs Syndrome Trial: Pramipexole Versus Levodopa/Benserazide

Restless Legs Syndrome

Enrolment: 58 · Results not recorded

NCT02337751 ↗PHASE3completed

Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

Parkinson's Disease

Enrolment: 198 · Results not recorded

NCT00869791 ↗PHASE2completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Parkinson's Disease

Enrolment: 27 · Results not recorded

NCT00253084 ↗PHASE2completed

IPX054 Compared to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's Disease

Parkinson's Disease

Enrolment: 12 · Results not recorded

NCT03703570 ↗PHASE2completed

A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Levodopa-containing Preparations

Parkinson's Disease

Enrolment: 502 · Results not recorded

NCT02589340 ↗PHASE1terminated

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Parkinson's Disease · Dyskinesias · Movement Disorders

Enrolment: 6 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28288867 ↗2017Reported benefit

Moderate traumatic brain injury increases the vulnerability to neurotoxicity induced by systemic administration of 6-hydroxydopamine in mice.

MouseTBIWeight-drop / impact-accelerationSwissintraperitoneal25 mg/kgacute administration during the 4-week post-injury behavioural testing period

Model: Moderate traumatic brain injury using a free weight-drop device, followed 5 hours later by a single intraperitoneal injection of 6-hydroxydopamine 100 mg/kg

Mice given traumatic brain injury plus 6-hydroxydopamine showed significant motor and neurological impairment that was improved by acute levodopa at 25 mg/kg, alongside reduced rostral striatal tyrosine hydroxylase and increased glial fibrillary acidic protein.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…